BclXL (Bcl2l1) gene therapy lessens retinal ganglion cell soma loss but not axonal degeneration after acute axonal injury.

PubMed ID: 35869049

Author(s): Marola OJ, Yablonski SER, Shrager PG, Nickells RW, Libby RT. BclX(L) (Bcl2l1) gene therapy lessens retinal ganglion cell soma loss but not axonal degeneration after acute axonal injury. Cell Death Discov. 2022 Jul 22;8(1):331. doi: 10.1038/s41420-022-01111-4. PMID 35869049

Journal: Cell Death Discovery, Volume 8, Issue 1, Jul 2022